Maya Thanou

Maya Thanou is a professor of Pharmaceutical Nanotechnology at the Institute of Pharmaceutical Science, at the School of Cancer and Pharmaceutical Sciences, at King's College London. Maya has over 20 years of experience in nanomedicine, she has authored over 120 scientific articles and chapters and is a co-inventor on 10 patents/patent applications. Her research focuses on activatable drug delivery systems using imaging and non-invasive interventions such as focused ultrasound.



Maya is the CEO of a King’s College London spinout Apeikon Therapeutics. Apeikon's technology aims to make novel solutions for hard-to-treat tumors. Her research focuses on activatable drug delivery systems using imaging and non-invasive interventions such as focused ultrasound. Maya has also co-founded the startup AJMmed-i-caps which develops diagnostics for diseases of the gastrointestinal tract.